18 results on '"Gillardon F"'
Search Results
2. Cerebrospinal fluid proteome profile in patients with multiple sclerosis
- Author
-
Tauscher, G., Lehmensiek, V., Süßmuth, S.D., Ahlert, T., Felk, S., Gillardon, F., and Tumani, H.
- Published
- 2024
- Full Text
- View/download PDF
3. Supplementary Material for: Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia
- Author
-
Wilke, C., Gillardon, F., Deuschle, C., Hobert, M.A., Jansen, I.E., Metzger, F.G., Heutink, P., Gasser, T., Maetzler, W., Blauwendraat, C., and Synofzik, M.
- Subjects
mental disorders - Abstract
Background and Objective: Reduced progranulin levels are a hallmark of frontotemporal dementia (FTD) caused by loss-of-function (LoF) mutations in the progranulin gene (GRN). However, alterations of central nervous progranulin expression also occur in neurodegenerative disorders unrelated to GRN mutations, such as Alzheimer's disease. We hypothesised that central nervous progranulin levels are also reduced in GRN-negative FTD. Methods: Progranulin levels were determined in both cerebrospinal fluid (CSF) and serum in 75 subjects (37 FTD patients and 38 controls). All FTD patients were assessed by whole-exome sequencing for GRN mutations, yielding a target cohort of 34 patients without pathogenic mutations in GRN (GRN-negative cohort) and 3 GRN mutation carriers (2 LoF variants and 1 novel missense variant). Results: Not only the GRN mutation carriers but also the GRN-negative patients showed decreased CSF levels of progranulin (serum levels in GRN-negative patients were normal). The decreased CSF progranulin levels were unrelated to patients' increased CSF levels of total tau, possibly indicating different destructive neuronal processes within FTD neurodegeneration. The patient with the novel GRN missense variant (c.1117C>T, p.P373S) showed substantially decreased CSF levels of progranulin, comparable to the 2 patients with GRN LoF mutations, suggesting a pathogenic effect of this missense variant. Conclusions: Our results indicate that central nervous progranulin reduction is not restricted to the relatively rare cases of FTD caused by GRN LoF mutations, but also contributes to the more common GRN-negative forms of FTD. Central nervous progranulin reduction might reflect a partially distinct pathogenic mechanism underlying FTD neurodegeneration and is not directly linked to tau alterations.
- Published
- 2016
- Full Text
- View/download PDF
4. Changes in actin dynamics and F-actin structure both in synaptoneurosomes of LRRK2(R1441G) mutant mice and in primary human fibroblasts of LRRK2(G2019S) mutation carriers
- Author
-
Caesar, M., primary, Felk, S., additional, Aasly, J.O., additional, and Gillardon, F., additional
- Published
- 2015
- Full Text
- View/download PDF
5. Two engineered AAV capsid variants for efficient transduction of human cortical neurons directly converted from iPSC.
- Author
-
Fischer S, Strobel B, Weinmann J, and Gillardon F
- Subjects
- Animals, Capsid metabolism, Genetic Vectors, Humans, Neurons, Rats, Transduction, Genetic, Dependovirus genetics, Induced Pluripotent Stem Cells
- Abstract
Background: Recombinant adeno-associated virus (AAV) is the most widely used vector for gene therapy in clinical trials. To increase transduction efficiency and specificity, novel engineered AAV variants with modified capsid sequences are evaluated in human cell cultures and non-human primates., Methods: We tested two novel AAV capsid variants, AAV2-NNPTPSR and AAV9-NVVRSSS, in human cortical neurons, which were directly converted from human induced pluripotent stem cells and cocultured with rat primary astrocytes., Results: AAV2-NNPTPSR variant efficiently transduced both induced human cortical glutamatergic neurons and induced human cortical GABAergic interneurons. By contrast, AAV9-NVVRSSS variant transduced both induced human cortical neurons and cocultured rat primary astrocytes. High viral titers (1E+5 viral genomes per cell) caused a significant decrease in viability of induced human cortical neurons. Low viral titers (1E+4 viral genomes per cell) led to a significant increase in the neuronal activity marker c-Fos in transduced human neurons following treatment with a potassium channel blocker., Conclusions: We identified two engineered AAV capsid variants that efficiently transduce induced human cortical neurons. The threefold higher percentage of c-Fos positive, transduced human neurons may indicate functional alterations induced by viral transduction and/or transgene expression., (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
6. Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors.
- Author
-
Carter AM, Kumar N, Herring B, Tan C, Guenter R, Telange R, Howse W, Viol F, McCaw TR, Bickerton HH, Gupta P, Gillardon F, Woltering EA, Dhall D, Totenhagen J, Banerjee RR, Kurian EM, Reddy S, Chen H, Schrader J, Bart Rose J, Mukhtar MS, and Bibb JA
- Abstract
Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous population of neoplasms that arise from hormone-secreting islet cells of the pancreas and have increased markedly in incidence over the past four decades. Non-functional PanNETs, which occur more frequently than hormone-secreting tumors, are often not diagnosed until later stages of tumor development and have poorer prognoses. Development of successful therapeutics for PanNETs has been slow, partially due to a lack of diverse animal models for pre-clinical testing. Here, we report development of an inducible, conditional mouse model of PanNETs by using a bi-transgenic system for regulated expression of the aberrant activator of Cdk5, p25, specifically in β-islet cells. This model produces a heterogeneous population of PanNETs that includes a subgroup of well-differentiated, non-functional tumors. Production of these tumors demonstrates the causative potential of aberrantly active Cdk5 for generation of PanNETs. Further, we show that human PanNETs express Cdk5 pathway components, are dependent on Cdk5 for growth, and share genetic and transcriptional overlap with the INS-p25OE model. The utility of this model is enhanced by the ability to form tumor-derived allografts. This new model of PanNETs will facilitate molecular delineation of Cdk5-dependent PanNETs and the development of new targeted therapeutics., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
7. Neuronal Differentiation of Induced Pluripotent Stem Cells from Schizophrenia Patients in Two-Dimensional and in Three-Dimensional Cultures Reveals Increased Expression of the Kv4.2 Subunit DPP6 That Contributes to Decreased Neuronal Activity.
- Author
-
Naujock M, Speidel A, Fischer S, Kizner V, Dorner-Ciossek C, and Gillardon F
- Subjects
- Calcium metabolism, Cell Proliferation, Cell Survival, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases metabolism, GABAergic Neurons metabolism, Gene Expression Regulation, Glutamic Acid metabolism, Humans, Nerve Tissue Proteins metabolism, Neural Stem Cells metabolism, Potassium Channels metabolism, Protein Subunits metabolism, RNA, Messenger genetics, RNA, Messenger metabolism, Shal Potassium Channels metabolism, Spheroids, Cellular pathology, Synapses metabolism, Tissue Donors, Cell Culture Techniques, Cell Differentiation, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases genetics, Induced Pluripotent Stem Cells pathology, Nerve Tissue Proteins genetics, Neurons pathology, Potassium Channels genetics, Protein Subunits genetics, Schizophrenia pathology, Shal Potassium Channels genetics
- Abstract
Although the molecular underpinnings of schizophrenia (SZ) are still incompletely understood, deficits in synaptic activity and neuronal connectivity have been identified as core pathomechanisms of SZ and other neuropsychiatric disorders. In this study, we generated induced pluripotent stem cell (iPSC) lines from skin fibroblasts from healthy donors and patients diagnosed with idiopathic SZ. We differentiated the human iPSC into cortical neurons both as adherent monolayers and as three-dimensional spheroids. RNA sequencing revealed little overlap in differentially expressed genes between 2D and 3D neuron cultures from SZ iPSC compared with controls. Notably, mRNA transcripts encoding dipeptidyl peptidase-like protein 6 (DPP6), an accessory subunit of Kv4.2 voltage-gated potassium channels, were massively increased in cortical neurons from SZ iPSC in the 2D and 3D model. Consistently, multielectrode array recordings and calcium imaging showed significantly decreased neuronal activity both in 2D and in 3D cultures from SZ neurons. To show a causal relationship, we treated iPSC-derived neurons in 2D cultures with lentiviral DPP6 shRNA vectors and the Kv4.2 channel blocker AmmTx3, respectively. Both treatments successfully reversed neuronal hypoexcitability and hypoactivity in cortical neurons from SZ iPSC. Our data highlight a contribution of DPP6 and Kv4.2 to the deficit in neurotransmission in an iPSC model for SZ, which may be of therapeutic relevance for a subset of SZ patients.
- Published
- 2020
- Full Text
- View/download PDF
8. Loss-of-function Mutations of CUL3, a High Confidence Gene for Psychiatric Disorders, Lead to Aberrant Neurodevelopment In Human Induced Pluripotent Stem Cells.
- Author
-
Fischer S, Schlotthauer I, Kizner V, Macartney T, Dorner-Ciossek C, and Gillardon F
- Subjects
- Cell Differentiation, Cullin Proteins genetics, Female, Humans, Mutation, Pregnancy, Induced Pluripotent Stem Cells, Mental Disorders, Neural Stem Cells
- Abstract
Both rare, high risk, loss-of-function mutations and common, low risk, genetic variants in the CUL3 gene are strongly associated with neuropsychiatric disorders. Network analyses of neuropsychiatric risk genes have shown high CUL3 expression in the prenatal human brain and an enrichment in neural precursor cells (NPCs) and cortical neurons. The role of CUL3 in human neurodevelopment however, is poorly understood. In the present study, we used CRISPR/Cas9 nickase to knockout CUL3 in human induced pluripotent stem cells (iPSCs). iPSCs were subsequently differentiated into cortical glutamatergic neurons using two different protocols and tested for structural/functional alterations. Immunocytochemical analysis and transcriptomic profiling revealed that pluripotency of heterozygous CUL3 knockout (KO) iPSCs remained unchanged compared to isogenic control iPSCs. Following small molecule-mediated differentiation into cortical glutamatergic neurons however, we detected a significant delay in transition from proliferating radial glia cells/NPCs to postmitotic neurons in CUL3 KO cultures. Notably, direct neural conversion of CUL3 KO iPSCs by lentiviral expression of Neurogenin-2 massively attenuated the neurodevelopmental delay. However, both optogenetic and electrical stimulation of induced neurons revealed decreased excitability in Cullin-3 deficient cultures, while basal synaptic transmission remained unchanged. Analysis of target gene expression pointed to alterations in FGF signaling in CUL3 KO NPCs, which is required for NPC proliferation and self-renewal, while RhoA and Notch signaling appeared unaffected. Our data provide first evidence for a major role of Cullin-3 in neuronal differentiation, and for neurodevelopmental deficits underlying neuropsychiatric disorders associated with CUL3 mutations., (Copyright © 2020 IBRO. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
9. Phosphoprotein-based biomarkers as predictors for cancer therapy.
- Author
-
Carter AM, Tan C, Pozo K, Telange R, Molinaro R, Guo A, De Rosa E, Martinez JO, Zhang S, Kumar N, Takahashi M, Wiederhold T, Ghayee HK, Oltmann SC, Pacak K, Woltering EA, Hatanpaa KJ, Nwariaku FE, Grubbs EG, Gill AJ, Robinson B, Gillardon F, Reddy S, Jaskula-Sztul R, Mobley JA, Mukhtar MS, Tasciotti E, Chen H, and Bibb JA
- Subjects
- Animals, Biomarkers analysis, Biomarkers metabolism, Cyclin-Dependent Kinase 5 antagonists & inhibitors, Cyclin-Dependent Kinase 5 genetics, Cyclin-Dependent Kinase 5 metabolism, Heterografts, Humans, Mice, Neoplasms genetics, Neuroectodermal Tumors genetics, Neuroectodermal Tumors metabolism, Phosphoproteins analysis, Phosphoproteins genetics, Phosphorylation, Neoplasms drug therapy, Neoplasms metabolism, Neuroectodermal Tumors drug therapy, Phosphoproteins metabolism, Protein Kinase Inhibitors administration & dosage
- Abstract
Disparities in cancer patient responses have prompted widespread searches to identify differences in sensitive vs. nonsensitive populations and form the basis of personalized medicine. This customized approach is dependent upon the development of pathway-specific therapeutics in conjunction with biomarkers that predict patient responses. Here, we show that Cdk5 drives growth in subgroups of patients with multiple types of neuroendocrine neoplasms. Phosphoproteomics and high throughput screening identified phosphorylation sites downstream of Cdk5. These phosphorylation events serve as biomarkers and effectively pinpoint Cdk5-driven tumors. Toward achieving targeted therapy, we demonstrate that mouse models of neuroendocrine cancer are responsive to selective Cdk5 inhibitors and biomimetic nanoparticles are effective vehicles for enhanced tumor targeting and reduction of drug toxicity. Finally, we show that biomarkers of Cdk5-dependent tumors effectively predict response to anti-Cdk5 therapy in patient-derived xenografts. Thus, a phosphoprotein-based diagnostic assay combined with Cdk5-targeted therapy is a rational treatment approach for neuroendocrine malignancies., Competing Interests: The authors declare no competing interest.
- Published
- 2020
- Full Text
- View/download PDF
10. CRISPR/Cas9-mediated Knockout of the Neuropsychiatric Risk Gene KCTD13 Causes Developmental Deficits in Human Cortical Neurons Derived from Induced Pluripotent Stem Cells.
- Author
-
Kizner V, Naujock M, Fischer S, Jäger S, Reich S, Schlotthauer I, Zuckschwerdt K, Geiger T, Hildebrandt T, Lawless N, Macartney T, Dorner-Ciossek C, and Gillardon F
- Subjects
- Base Sequence, CRISPR-Associated Protein 9 metabolism, Cell Differentiation, Cell Proliferation, DNA biosynthesis, Humans, Neural Stem Cells metabolism, Neurites metabolism, Nuclear Proteins deficiency, Receptor, ErbB-2 metabolism, Risk Factors, rhoA GTP-Binding Protein metabolism, CRISPR-Cas Systems genetics, Cerebral Cortex pathology, Gene Knockout Techniques, Genetic Predisposition to Disease, Induced Pluripotent Stem Cells pathology, Mental Disorders genetics, Neurons pathology, Nuclear Proteins genetics
- Abstract
The human KCTD13 gene is located within the 16p11.2 locus and copy number variants of this locus are associated with a high risk for neuropsychiatric diseases including autism spectrum disorder and schizophrenia. Studies in zebrafish point to a role of KCTD13 in proliferation of neural precursor cells which may contribute to macrocephaly in 16p11.2 deletion carriers. KCTD13 is highly expressed in the fetal human brain and in mouse cortical neurons, but its contribution to the development and function of mammalian neurons is not completely understood. In the present study, we deleted the KCTD13 gene in human-induced pluripotent stem cells (iPSCs) using CRISPR/Cas9 nickase. Following neural differentiation of KCTD13 deficient and isogenic control iPSC lines, we detected a moderate but significant inhibition of DNA synthesis and proliferation in KCTD13 deficient human neural precursor cells. KCTD13 deficient cortical neurons derived from iPSCs showed decreased neurite formation and reduced spontaneous network activity. RNA-sequencing and pathway analysis pointed to a role for ERBB signaling in these phenotypic changes. Consistently, activating and inhibiting ERBB kinases rescued and aggravated, respectively, impaired neurite formation. In contrast to findings in non-neuronal human HeLa cells, we did not detect an accumulation of the putative KCTD13/Cullin-3 substrate RhoA, and treatment with inhibitors of RhoA signaling did not rescue decreased neurite formation in human KCTD13 knockout neurons. Taken together, our data provide insight into the role of KCTD13 in neurodevelopmental disorders, and point to ERBB signaling as a potential target for neuropsychiatric disorders associated with KCTD13 deficiency.
- Published
- 2020
- Full Text
- View/download PDF
11. Age-related pathology after adenoviral overexpression of the leucine-rich repeat kinase 2 in the mouse striatum.
- Author
-
Kritzinger A, Ferger B, Gillardon F, Stierstorfer B, Birk G, Kochanek S, and Ciossek T
- Subjects
- Animals, Disease Models, Animal, Genetic Predisposition to Disease genetics, Inflammation etiology, Inflammation genetics, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 administration & dosage, Male, Mice, Inbred C57BL, Mutation, Neuroglia metabolism, Adenoviridae genetics, Aging genetics, Aging pathology, Corpus Striatum metabolism, Corpus Striatum pathology, Gene Expression, Genetic Vectors genetics, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 genetics, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 metabolism, Parkinson Disease etiology, Parkinson Disease genetics
- Abstract
Mutations in leucine-rich repeat kinase 2 (LRRK2) age-dependently cause Parkinson's disease and are associated with several inflammatory diseases. So far, the potential role of LRRK2 expression in glial cells as mediators of neuroinflammation and the influence of aging have not been investigated in viral vector-based LRRK2 animal models. In this study, we compared the effect of striatal injection of high-capacity adenoviral vectors expressing either a kinase-overactive LRRK2 with the familial G2019S mutation or a kinase-inactive LRRK2 variant in young and old C57BL/6J mice. The intrinsic adenovirus tropism guided preferentially glial transduction, and the vector design led to stable expression for at least 6 months. In histopathological analysis, young mice expressing either LRRK2 variant presented with transient vacuolization of striatal white fiber tracts accompanied by accumulation of microglial cells and astrogliosis, but inflammation resolved without permanent damage. Old mice had a stronger and prolonged inflammatory reaction and experienced permanent damage in form of partial neuron loss after 3 months exclusively in case of LRRK2_G2019S expression. The autophagic receptor p62 accumulated in cells with high levels of either LRRK2 variant, even more so in old mice. We conclude that the aging mouse brain is more susceptible to LRRK2-associated pathology, and in this model, glial LRRK2 expression significantly contributed to neuroinflammation, ultimately causing neurodegeneration., (Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
12. Proteasome impairment by α-synuclein.
- Author
-
Zondler L, Kostka M, Garidel P, Heinzelmann U, Hengerer B, Mayer B, Weishaupt JH, Gillardon F, and Danzer KM
- Subjects
- Animals, Blotting, Western, Dopaminergic Neurons drug effects, Fluorescent Antibody Technique, Humans, Microscopy, Atomic Force, PC12 Cells, Parkinson Disease etiology, Proteasome Endopeptidase Complex ultrastructure, Rats, Recombinant Proteins, Proteasome Endopeptidase Complex drug effects, alpha-Synuclein pharmacology
- Abstract
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide and characterized by the loss of dopaminergic neurons in the patients' midbrains. Both the presence of the protein α-synuclein in intracellular protein aggregates in surviving neurons and the genetic linking of the α-synuclein encoding gene point towards a major role of α-synuclein in PD etiology. The exact pathogenic mechanisms of PD development are not entirely described to date, neither is the specific role of α-synuclein in this context. Previous studies indicate that one aspect of α-synuclein-related cellular toxicity might be direct proteasome impairment. The 20/26S proteasomal machinery is an important instrument of intracellular protein degradation. Thus, direct proteasome impairment by α-synuclein might explain or at least contribute to the formation of intracellular protein aggregates. Therefore this study investigates direct proteasomal impairment by α-synuclein both in vitro using recombinant α-synuclein and isolated proteasomes as well as in living cells. Our experiments demonstrate that the impairment of proteasome activity by α-synuclein is highly dependent upon the cellular background and origin. We show that recombinant α-synuclein oligomers and fibrils scarcely affect 20S proteasome function in vitro, neither does transient α-synuclein expression in U2OS ps 2042 (Ubi(G76V)-GFP) cells. However, stable expression of both wild-type and mutant α-synuclein in dopaminergic SH-SY5Y and PC12 cells results in a prominent impairment of the chymotrypsin-like 20S/26S proteasomal protein cleavage. Thus, our results support the idea that α-synuclein in a specific cellular environment, potentially present in dopaminergic cells, cannot be processed by the proteasome and thus contributes to a selective vulnerability of dopaminergic cells to α-synuclein pathology.
- Published
- 2017
- Full Text
- View/download PDF
13. Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia.
- Author
-
Wilke C, Gillardon F, Deuschle C, Hobert MA, Jansen IE, Metzger FG, Heutink P, Gasser T, Maetzler W, Blauwendraat C, and Synofzik M
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Mutation, Mutation, Missense, Phosphorylation, Polymorphism, Single Nucleotide, Progranulins, tau Proteins cerebrospinal fluid, tau Proteins metabolism, Frontotemporal Dementia blood, Frontotemporal Dementia cerebrospinal fluid, Frontotemporal Dementia genetics, Intercellular Signaling Peptides and Proteins blood, Intercellular Signaling Peptides and Proteins cerebrospinal fluid, Intercellular Signaling Peptides and Proteins genetics
- Abstract
Background and Objective: Reduced progranulin levels are a hallmark of frontotemporal dementia (FTD) caused by loss-of-function (LoF) mutations in the progranulin gene (GRN). However, alterations of central nervous progranulin expression also occur in neurodegenerative disorders unrelated to GRN mutations, such as Alzheimer's disease. We hypothesised that central nervous progranulin levels are also reduced in GRN-negative FTD., Methods: Progranulin levels were determined in both cerebrospinal fluid (CSF) and serum in 75 subjects (37 FTD patients and 38 controls). All FTD patients were assessed by whole-exome sequencing for GRN mutations, yielding a target cohort of 34 patients without pathogenic mutations in GRN (GRN-negative cohort) and 3 GRN mutation carriers (2 LoF variants and 1 novel missense variant)., Results: Not only the GRN mutation carriers but also the GRN-negative patients showed decreased CSF levels of progranulin (serum levels in GRN-negative patients were normal). The decreased CSF progranulin levels were unrelated to patients' increased CSF levels of total tau, possibly indicating different destructive neuronal processes within FTD neurodegeneration. The patient with the novel GRN missense variant (c.1117C>T, p.P373S) showed substantially decreased CSF levels of progranulin, comparable to the 2 patients with GRN LoF mutations, suggesting a pathogenic effect of this missense variant., Conclusions: Our results indicate that central nervous progranulin reduction is not restricted to the relatively rare cases of FTD caused by GRN LoF mutations, but also contributes to the more common GRN-negative forms of FTD. Central nervous progranulin reduction might reflect a partially distinct pathogenic mechanism underlying FTD neurodegeneration and is not directly linked to tau alterations., (© 2016 S. Karger AG, Basel.)
- Published
- 2017
- Full Text
- View/download PDF
14. LRRK2 contributes to monocyte dysregulation in Parkinson's disease.
- Author
-
Bliederhaeuser C, Zondler L, Grozdanov V, Ruf WP, Brenner D, Melrose HL, Bauer P, Ludolph AC, Gillardon F, Kassubek J, Weishaupt JH, and Danzer KM
- Subjects
- Aged, Animals, B-Lymphocytes metabolism, GPI-Linked Proteins metabolism, Humans, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 deficiency, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 genetics, Lipopolysaccharide Receptors metabolism, Mice, Transgenic, Receptors, IgG metabolism, Spleen metabolism, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 metabolism, Monocytes metabolism, Parkinsonian Disorders metabolism
- Published
- 2016
- Full Text
- View/download PDF
15. Leucine-Rich Repeat Kinase 2 Influences Fate Decision of Human Monocytes Differentiated from Induced Pluripotent Stem Cells.
- Author
-
Speidel A, Felk S, Reinhardt P, Sterneckert J, and Gillardon F
- Subjects
- Cell Line, Humans, Cell Differentiation genetics, Induced Pluripotent Stem Cells cytology, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 genetics, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 metabolism, Monocytes cytology, Mutation
- Abstract
Mutations in Leucine-rich repeat kinase 2 (LRRK2) are strongly associated with familial Parkinson's disease (PD). High expression levels in immune cells suggest a role of LRRK2 in regulating the immune system. In this study, we investigated the effect of the LRRK2 (G2019S) mutation in monocytes, using a human stem cell-derived model expressing LRRK2 at endogenous levels. We discovered alterations in the differentiation pattern of LRRK2 mutant, compared to non-mutant isogenic controls, leading to accelerated monocyte production and a reduction in the non-classical CD14+CD16+ monocyte subpopulation in the LRRK2 mutant cells. LPS-treatment of the iPSC-derived monocytes significantly increased the release of pro-inflammatory cytokines, demonstrating a functional response without revealing any significant differences between the genotypes. Assessment of the migrational capacity of the differentiated monocytes revealed moderate deficits in LRRK2 mutant cells, compared to their respective controls. Our findings indicate a pivotal role of LRRK2 in hematopoietic fate decision, endorsing the involvement of the immune system in the development of PD., Competing Interests: Anna Speidel, Sandra Felk and Frank Gillardon are employed by Boehringer Ingelheim Pharma GmbH & Co. KG. This does neither constitute conflicts of interest regarding the present study nor does it alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2016
- Full Text
- View/download PDF
16. Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes.
- Author
-
Bliederhaeuser C, Grozdanov V, Speidel A, Zondler L, Ruf WP, Bayer H, Kiechle M, Feiler MS, Freischmidt A, Brenner D, Witting A, Hengerer B, Fändrich M, Ludolph AC, Weishaupt JH, Gillardon F, and Danzer KM
- Subjects
- Animals, Cells, Cultured, Chromatography, Gel, Enzyme-Linked Immunosorbent Assay, Exosomes metabolism, Female, Flow Cytometry, Humans, Immunoblotting, Mice, Parkinson Disease metabolism, Phagocytosis physiology, Aging metabolism, Microglia metabolism, Monocytes metabolism, alpha-Synuclein metabolism
- Abstract
Extracellular alpha-synuclein (αsyn) oligomers, associated to exosomes or free, play an important role in the pathogenesis of Parkinson's disease (PD). Increasing evidence suggests that these extracellular moieties activate microglia leading to enhanced neuronal damage. Despite extensive efforts on studying neuroinflammation in PD, little is known about the impact of age on microglial activation and phagocytosis, especially of extracellular αsyn oligomers. Here, we show that microglia isolated from adult mice, in contrast to microglia from young mice, display phagocytosis deficits of free and exosome-associated αsyn oligomers combined with enhanced TNFα secretion. In addition, we describe a dysregulation of monocyte subpopulations with age in mice and humans. Accordingly, human monocytes from elderly donors also show reduced phagocytic activity of extracellular αsyn. These findings suggest that these age-related alterations may contribute to an increased susceptibility to pathogens or abnormally folded proteins with age in neurodegenerative diseases.
- Published
- 2016
- Full Text
- View/download PDF
17. Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease.
- Author
-
Wilke C, Gillardon F, Deuschle C, Dubois E, Hobert MA, Müller vom Hagen J, Krüger S, Biskup S, Blauwendraat C, Hruscha M, Kaeser SA, Heutink P, Maetzler W, and Synofzik M
- Subjects
- Aged, Alzheimer Disease genetics, Amyotrophic Lateral Sclerosis genetics, Biomarkers blood, Biomarkers cerebrospinal fluid, Female, Frontotemporal Dementia genetics, Humans, Intercellular Signaling Peptides and Proteins genetics, Male, Middle Aged, Progranulins, Alzheimer Disease metabolism, Amyotrophic Lateral Sclerosis metabolism, Frontotemporal Dementia metabolism, Intercellular Signaling Peptides and Proteins blood, Intercellular Signaling Peptides and Proteins cerebrospinal fluid
- Abstract
Altered progranulin levels play a major role in neurodegenerative diseases, like Alzheimer's dementia (AD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), even in the absence of GRN mutations. Increasing progranulin levels could hereby provide a novel treatment strategy. However, knowledge on progranulin regulation in neurodegenerative diseases remains limited. We here demonstrate that cerebrospinal fluid progranulin levels do not correlate with its serum levels in AD, FTD and ALS, indicating a differential regulation of its central and peripheral levels in neurodegeneration. Blood progranulin levels thus do not reliably predict central nervous progranulin levels and their response to future progranulin-increasing therapeutics.
- Published
- 2016
- Full Text
- View/download PDF
18. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
- Author
-
Garcia-Miralles M, Coomaraswamy J, Häbig K, Herzig MC, Funk N, Gillardon F, Maisel M, Jucker M, Gasser T, Galter D, and Biskup S
- Subjects
- Adult, Aged, Aged, 80 and over, Animals, Cytoskeleton drug effects, Female, Fibroblasts cytology, Fibroblasts drug effects, Fibroblasts metabolism, Gene Expression, Humans, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Male, Mice, Mice, Transgenic, Middle Aged, Neurites drug effects, Neurites metabolism, Parkinson Disease enzymology, Parkinson Disease genetics, Protein Kinase Inhibitors pharmacology, Protein Serine-Threonine Kinases antagonists & inhibitors, Cytoskeleton metabolism, Dopamine metabolism, Mutation, Protein Serine-Threonine Kinases genetics
- Abstract
Mutations within the LRRK2 gene have been identified in Parkinson's disease (PD) patients and have been implicated in the dysfunction of several cellular pathways. Here, we explore how pathogenic mutations and the inhibition of LRRK2 kinase activity affect cytoskeleton dynamics in mouse and human cell systems. We generated and characterized a novel transgenic mouse model expressing physiological levels of human wild type and G2019S-mutant LRRK2. No neuronal loss or neurodegeneration was detected in midbrain dopamine neurons at the age of 12 months. Postnatal hippocampal neurons derived from transgenic mice showed no alterations in the seven parameters examined concerning neurite outgrowth sampled automatically on several hundred neurons using high content imaging. Treatment with the kinase inhibitor LRRK2-IN-1 resulted in no significant changes in the neurite outgrowth. In human fibroblasts we analyzed whether pathogenic LRRK2 mutations change cytoskeleton functions such as cell adhesion. To this end we compared the adhesion characteristics of human skin fibroblasts derived from six PD patients carrying one of three different pathogenic LRRK2 mutations and from four age-matched control individuals. The mutant LRRK2 variants as well as the inhibition of LRRK2 kinase activity did not reveal any significant cell adhesion differences in cultured fibroblasts. In summary, our results in both human and mouse cell systems suggest that neither the expression of wild type or mutant LRRK2, nor the inhibition of LRRK2 kinase activity affect neurite complexity and cellular adhesion.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.